Informing the Historical Record of Experimental Nonhuman Primate Infections with Ebola Virus: Genomic Characterization of USAMRIID Ebola Virus/H.sapiens-tc/COD/1995/Kikwit-9510621 Challenge Stock "R4368" and Its Replacement "R4415"

The creation of licensed medical countermeasures against Select Agents such as Ebola virus (EBOV) is critically dependent on the use of standardized reagents, assays, and animal models. We performed full genome reconstruction, population genomics, contaminant analysis, and characterization of the gl...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-03, Vol.11 (3), p.e0150919
Main Authors: Kugelman, Jeffrey R, Rossi, Cynthia A, Wiley, Michael R, Ladner, Jason T, Nagle, Elyse R, Pfeffer, Bradley P, Garcia, Karla, Prieto, Karla, Wada, Jiro, Kuhn, Jens H, Palacios, Gustavo
Format: Article
Language:English
Subjects:
Academies and Institutes
Animal models
Animals
Biology and Life Sciences
Care and treatment
Causes of
Contaminants
Correlation analysis
Ebola hemorrhagic fever
Ebola virus
Ebolavirus
Ebolavirus - genetics
Epidemics
Genetic modification
Genome editing
Genomes
Genomics - methods
Glycoproteins
Glycoproteins - genetics
Hemorrhagic Fever, Ebola - virology
Historic buildings & sites
Historic sites
Infections
Infectious diseases
Medical research
Medicine and Health Sciences
Monkeys & apes
Mutants
Mutation
Pathogenesis
Peptides
Physical Sciences
Physiological aspects
Primates
Primates - virology
Reagents
RNA polymerase
United States
Viral diseases
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The creation of licensed medical countermeasures against Select Agents such as Ebola virus (EBOV) is critically dependent on the use of standardized reagents, assays, and animal models. We performed full genome reconstruction, population genomics, contaminant analysis, and characterization of the glycoprotein gene editing site of historical United States Army Medical Research Institute of Infectious Diseases (USAMRIID) nonhuman-primate challenge stock Ebola virus Kikwit "R4368" and its 2014 replacement "R4415." We also provide characterization of the master stock used to create "R4415." The obtained data are essential to understanding the quality of the seed stock reagents used in pivotal animal studies that have been used to inform medical countermeasure development. Furthermore, these data might add to the understanding of the influence of EBOV variant populations on pathogenesis and disease outcome and inform attempts to avoid the evolution of EBOV escape mutants in response to current therapeutics. Finally, as the primary challenge stocks have changed over time, these data will provide a baseline for understanding and correlating past and future animal study results.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0150919